DK2155717T3 - 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl-pyraziner og -pyridiner og 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl-pyridiner som 5-ht7-receptorantagonister - Google Patents
2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl-pyraziner og -pyridiner og 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl-pyridiner som 5-ht7-receptorantagonisterInfo
- Publication number
- DK2155717T3 DK2155717T3 DK08747748.5T DK08747748T DK2155717T3 DK 2155717 T3 DK2155717 T3 DK 2155717T3 DK 08747748 T DK08747748 T DK 08747748T DK 2155717 T3 DK2155717 T3 DK 2155717T3
- Authority
- DK
- Denmark
- Prior art keywords
- ylalkyl
- pyridines
- piperazin
- pyrazol
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91743107P | 2007-05-11 | 2007-05-11 | |
| US97420907P | 2007-09-21 | 2007-09-21 | |
| PCT/US2008/062834 WO2008141020A1 (en) | 2007-05-11 | 2008-05-07 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2155717T3 true DK2155717T3 (da) | 2012-11-19 |
Family
ID=39629131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08747748.5T DK2155717T3 (da) | 2007-05-11 | 2008-05-07 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl-pyraziner og -pyridiner og 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl-pyridiner som 5-ht7-receptorantagonister |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8202873B2 (da) |
| EP (1) | EP2155717B1 (da) |
| JP (1) | JP5210375B2 (da) |
| KR (1) | KR101119294B1 (da) |
| CN (1) | CN101861312B (da) |
| AU (1) | AU2008251584B2 (da) |
| BR (1) | BRPI0811446A2 (da) |
| CA (1) | CA2684563C (da) |
| CY (1) | CY1113457T1 (da) |
| DK (1) | DK2155717T3 (da) |
| EA (1) | EA016529B1 (da) |
| ES (1) | ES2395872T3 (da) |
| HR (1) | HRP20120919T1 (da) |
| MX (1) | MX2009012126A (da) |
| PL (1) | PL2155717T3 (da) |
| PT (1) | PT2155717E (da) |
| WO (1) | WO2008141020A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410277B2 (en) | 2007-12-26 | 2013-04-02 | Eisai R&D Managment Co., Ltd. | Method for manufacturing heterocycle substituted pyridine derivatives |
| BR112012008128B8 (pt) * | 2009-07-31 | 2019-07-16 | Syngenta Participations Ag | processos para a preparação de um composto da fórmula | e processo para a alquilação regiosseletiva de um composto da fórmula || |
| US20130005710A1 (en) | 2009-11-18 | 2013-01-03 | Tetsuya Tsukamoto | Aminopyridine derivative |
| WO2011140333A1 (en) | 2010-05-07 | 2011-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of stabilizers of multimeric proteins |
| WO2012019950A1 (en) * | 2010-08-10 | 2012-02-16 | Syngenta Participations Ag | Process for the preparation of 3-haloalkylpyrazoles |
| MY179509A (en) * | 2013-12-20 | 2020-11-09 | Esteve Pharmaceuticals Sa | Piperazine derivatives having multimodal activity against pain |
| US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
| CN104592199A (zh) * | 2015-01-22 | 2015-05-06 | 杭州利巴医药科技有限公司 | 一种取代的1-(2-吡啶基)-吡唑-4-基乙酸及其衍生物和制备方法 |
| CN104945325B (zh) * | 2015-06-19 | 2017-04-05 | 浙江永太科技股份有限公司 | 一种吡唑甲酸衍生物的制备方法 |
| SG11201906922TA (en) | 2017-02-17 | 2019-09-27 | Eidos Therapeutics Inc | Processes for preparing ag-10, its intermediates, and salts thereof |
| CA3094711A1 (en) | 2018-03-23 | 2019-09-26 | Eidos Therapeutics, Inc. | Methods of treating ttr amyloidosis using ag10 |
| TWI834708B (zh) | 2018-08-17 | 2024-03-11 | 美商文涵治療有限公司 | Ag10之調配物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2079323B1 (es) * | 1994-06-21 | 1996-10-16 | Vita Invest Sa | Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes. |
| EP1676844A1 (en) * | 2004-12-28 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
| BRPI0406704A (pt) * | 2003-01-31 | 2005-12-20 | Pfizer Prod Inc | Antagonistas de 5ht~7~ e agonistas inversos |
| US20050080076A1 (en) * | 2003-10-08 | 2005-04-14 | Xanodyne Pharmacal, Inc. | N-desmethyl levomepromazine |
-
2008
- 2008-05-07 EA EA200971052A patent/EA016529B1/ru not_active IP Right Cessation
- 2008-05-07 MX MX2009012126A patent/MX2009012126A/es active IP Right Grant
- 2008-05-07 PT PT87477485T patent/PT2155717E/pt unknown
- 2008-05-07 AU AU2008251584A patent/AU2008251584B2/en not_active Ceased
- 2008-05-07 BR BRPI0811446-3A2A patent/BRPI0811446A2/pt not_active Application Discontinuation
- 2008-05-07 CA CA2684563A patent/CA2684563C/en not_active Expired - Fee Related
- 2008-05-07 ES ES08747748T patent/ES2395872T3/es active Active
- 2008-05-07 PL PL08747748T patent/PL2155717T3/pl unknown
- 2008-05-07 EP EP08747748A patent/EP2155717B1/en not_active Not-in-force
- 2008-05-07 DK DK08747748.5T patent/DK2155717T3/da active
- 2008-05-07 CN CN200880015741.XA patent/CN101861312B/zh not_active Expired - Fee Related
- 2008-05-07 WO PCT/US2008/062834 patent/WO2008141020A1/en active Application Filing
- 2008-05-07 US US12/597,255 patent/US8202873B2/en not_active Expired - Fee Related
- 2008-05-07 JP JP2010507607A patent/JP5210375B2/ja not_active Expired - Fee Related
- 2008-05-07 KR KR1020097022901A patent/KR101119294B1/ko not_active IP Right Cessation
-
2012
- 2012-11-13 HR HRP20120919AT patent/HRP20120919T1/hr unknown
- 2012-12-13 CY CY20121101219T patent/CY1113457T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2155717T3 (pl) | 2013-03-29 |
| BRPI0811446A2 (pt) | 2014-10-29 |
| EA200971052A1 (ru) | 2010-04-30 |
| AU2008251584A1 (en) | 2008-11-20 |
| EP2155717A1 (en) | 2010-02-24 |
| US20100120785A1 (en) | 2010-05-13 |
| CA2684563C (en) | 2013-08-13 |
| EA016529B1 (ru) | 2012-05-30 |
| US8202873B2 (en) | 2012-06-19 |
| JP5210375B2 (ja) | 2013-06-12 |
| KR20090127436A (ko) | 2009-12-11 |
| AU2008251584B2 (en) | 2013-04-11 |
| CN101861312B (zh) | 2014-09-03 |
| ES2395872T3 (es) | 2013-02-15 |
| WO2008141020A1 (en) | 2008-11-20 |
| PT2155717E (pt) | 2012-12-21 |
| JP2010526819A (ja) | 2010-08-05 |
| KR101119294B1 (ko) | 2012-04-12 |
| CA2684563A1 (en) | 2008-11-20 |
| MX2009012126A (es) | 2009-11-23 |
| EP2155717B1 (en) | 2012-10-24 |
| CY1113457T1 (el) | 2016-06-22 |
| HRP20120919T1 (hr) | 2012-12-31 |
| CN101861312A (zh) | 2010-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2155717T3 (da) | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl-pyraziner og -pyridiner og 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl-pyridiner som 5-ht7-receptorantagonister | |
| ATE516272T1 (de) | 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one | |
| CY2017038I1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν 4-(4-(3-(4-χλωρο-3-τριφθορομεθυλ-φαινυλ)-ουρειδο)-3-φθορο-φαινοξυ)-πυριδιν-2-καρβοξυλικο οξυ για thν θεραπευτικη αγωγη υπερπολλαπλασιαστικων διαταραχων | |
| DK1857457T3 (da) | Benzimidazolderivat og dets anvendelse som All-receptor-antagonist | |
| DK2234985T3 (da) | 4-(4-cyano-2-thioaryl)-dihydropyrimidinoner og deres anvendelse | |
| DK2049478T3 (da) | Substituerede N-phenylmethyl-5-oxoprolin-2-amider som P2X7-receptorantagonister og fremgangsmåder til anvendelse deraf | |
| DK2401269T3 (da) | Indolderivater som crth2-receptorantagonister | |
| DK2162131T3 (da) | Quinolin-derivativer som pi3-kinase-inhibitorer | |
| BRPI0817537A2 (pt) | 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona | |
| DK2170864T3 (da) | Pyridon-GPR119-G-protein-koblede receptoragonister | |
| DK2231614T3 (da) | Quinolinderivativer og anvendelse af disse som fungicider | |
| DK2099447T3 (da) | Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer | |
| DK2252597T3 (da) | Pyrazinderivater og deres anvendelse som proteinkinaseinhibitorer | |
| DK2188268T3 (da) | Substituerede piperazinylpyraziner og pyridiner som 5-HT7-receptorantagonister | |
| DK2066324T3 (da) | Cycloalkanpyrrolocarbazolderivater og anvendelse deraf som parp, vegfr2 og mlk3 inhibitorer | |
| FI20070924A0 (fi) | Hissin valmiustila | |
| DK2238110T3 (da) | 5.6-bisaryl-2-pyridin-carboxamid-derivater, fremstilling heraf og terapeutisk anvendelse heraf som urotensin II-receptorantagonister | |
| DK2069310T3 (da) | Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister | |
| DK2059508T3 (da) | 5,6-bisaryl-2-pyridin-carboxamidderivater, fremstilling deraf og terapeutisk anvendelse deraf som urotensin II-receptorantagonister | |
| DK2205569T3 (da) | Alkylthiopyrimidiner som crth2-antagonister | |
| DK2448927T3 (da) | Hidtil ukendte (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amidderivater, fremstilling deraf og farmaceutisk anvendelse deraf som akt-phosphoryleringshæmmere | |
| DK2358675T3 (da) | 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser | |
| DK2285784T3 (da) | 2-methyl-1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazol som 5-hydroxytryptamin-6-ligand | |
| BRPI0817835A2 (pt) | Antagonistas cgrp | |
| ATE534628T1 (de) | Urotensin ii-rezeptorantagonisten |